Cystic Fibrosis Foundation Awards Up to $3.5M to Arrevus Inc. to Develop Treatment for Pulmonary Exacerbations

The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.

Jan. 6, 2022 | 1 min read

The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial. Pulmonary exacerbations are a sudden worsening of respiratory symptoms caused by lung infections that often require IV antibiotic treatment.

Arrevus’ potential treatment, ACG-701, is the company’s own version of sodium fusidate. It is a compound that is used to treat methicillin-resistant Staphylococcus aureus, a cause of some CF lung infections, and may also decrease inflammation and mucus production. Sodium fusidate has been used in Europe, but it has never been approved in the U.S. Arrevus’ potential treatment comes in oral tablet form. The study is planned to begin in 2022.

Arrevus is a wholly owned subsidiary of Aceragen.

Share this article
Topics
About the CF Foundation | Clinical Trials | Our Research Approach
Recent news
Final Budget Reconciliation Bill May Pose Challenges for People With CF
News | 4 min read
More than 150 Advocates Urge Congress to Protect Coverage During the Cystic Fibrosis Foundation’s 17th annual Teen Advocacy Day
News | 3 min read
Survey Results Detail CF Community’s Ongoing Challenges and Commitment to a Cure for All With CF
News | 4 min read